Acquired skeletal muscle metabolic myopathy in atherosclerotic peripheral arterial disease

Vascular Medicine

Volumn 5, Issue 1, 2000, Pages 55-59

  Brass, Eric P ^a   Hiatt, William R ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b Univ of Colorado Hlth Sci Center ^*  (United States)

Author keywords

Carnitine; Mitochondria; Mitochondrial DNA; Peripheral arterial disease

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; ACYLCARNITINE; ADENOSINE TRIPHOSPHATE; CARNITINE; COENZYME A; MITOCHONDRIAL DNA; MITOCHONDRIAL ENZYME;

ARTERY DISEASE; ATHEROSCLEROSIS; CLAUDICATION; ENZYME ACTIVITY; GENE MUTATION; HUMAN; MITOCHONDRIAL RESPIRATION; MUSCLE METABOLISM; MYOPATHY; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE;

EID: 0034057221     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358836X0000500109     Document Type: Review

References (50)

1. Criqui MH, Fronek A, Barrett-Conner E, Klouber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985; 71: 510-15.
2. Hiatt WR, Marshall JA, Baxter J et al. Diagnostic methods for peripheral arterial disease in the San Luis Valley Diabetes Study. J Clin Epidemiol 1990; 43: 597-606.
3. Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-86.
4. Hiatt WR, Nawaz D, Brass EP. Carnitine metabolism during exercise in patients with peripheral vascular disease. J Appl Physiol 1987; 62: 2383-87.
5. Pernow B, Zelterquist S. Metabolic evaluation of the leg blood flow in claudication patients with arterial obstruction at different levels. Scand J Clin Lab Invest 1968; 21: 277-87.
6. Gardner AW, Skinner JS, Cantwell BW, Smith LK. Prediction of claudication pain from clinical measurements obtained at rest. Med Sci Sports Exerc 1992; 24: 163-70.
7. Regensteiner JG, Hargarten ME, Rutherford RB, Hiatt WR. Functional benefits of peripheral vascular bypass surgery for patients with intermittent claudication. Angiology 1993; 44: 1-10.
8. Hiatt WR, Regensteiner JG, Hargarten MC, Wolfel EE, Brass EP. Benefits of exercise conditioning for patients with peripheral arterial disease. Circulation 1990; 81: 602-09.
9. Holloszy JO. Biochemical adaptations in muscle. J Biol Chem 1967; 242: 2278-82.
10. Holloszy JO, Coyle EF. Adaptation of skeletal muscle to endurance exercise and their metabolic consequences. J Appl Physiol 1984; 56: 8831-38.
11. Hoppeler H, Luthi P, Clausen H, Weibel ER, Howard H. The ultrastructure of normal human skeletal muscle. A morphometric analysis of untrained men, women and well-trained volunteers. Pflugers Arch 1973; 344: 217-32.
12. Booth FW, Narahara KA. Vastus lateralis cytochrome oxidase activity and its relationship to maximal oxygen consumption in man. Pflugers Arch 1974; 349: 319-24.
13. Wibon R, Hultman E, Johansson M, Matherei K, Constantin-Theudosiu D, Schantz PG. Adaptation of mitochondrial ATP production in human skeletal muscle to endurance training and detraining. J Appl Physiol 1992; 73: 2004-10.
14. Davies KJA, Packer L, Brooks GA. Biochemical adaptation of mitochondria in muscle, and whole-animal respiration to endurance training. Arch Biochem Biophys 1981; 209: 539-54.
15. Reichmann H, Hoppeler H, Mathieu-Costello O, von Bergen F, Pette D. Biochemical and ultrastructural changes of skeletal muscle mitochondria after chronic electrical stimulation in rabbits. Pflugers Arch 1985; 404: 1-9.
16. Bylund AC, Hammersten J, Holm J, Schersten T. Enzyme activities in skeletal muscle from patients with peripheral arterial insufficiency. Eur J Clin Invest 1976; 6: 425-29.
17. Jansson E, Johansson J, Sylven C, Kaijser L. Calf muscle adaptation in intermittent claudication: side differences in muscle metabolic characteristics in patients with unilateral disease. Clin Physiol 1988; 8: 17-29.
18. Lundgren F, Dahllof AG, Schersten T, Bylund-Fellenius AC. Muscle enzyme adaptation in patients with peripheral arterial insufficiency: spontaneous adaptation, effect of different treatments and consequences on walking performance. Clin Sci 1989; 77: 485-93.
19. Hiatt WR, Regensteiner JG, Wolfel EE, Carry MR, Brass EP. Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease. J Appl Physiol 1996; 81: 780-88.
20. Dahllof A, Bjornterp P, Holm J, Schersten T. Metabolic activity of skeletal muscle in patients with peripheral arterial insufficiency. Effect of physical training. Eur J Clin Invest 1974; 4: 9-15.
21. Wallace DC. Diseases of the mitochondrial DNA. Annu Rev Biochem 1992; 61: 1175-1212.
22. Nagley P. Coordination of gene expression in the formation of mammalian mitochondria. Trends Genet 1991; 7: 1-4.
23. Hoppel CL, Kerr DS, Dahms B, Roessmann U. Deficiency of the reduced nicotinamide adenine dinucleotide dehydrogenase component of complex 1 of mitochondrial electron transport. J Clin Invest 1987; 80: 71-77.
24. Bhat HK Hiatt WR, Hoppel DL, Brass EP. Skeletal muscle mitochondrial DNA injury in patients with unilateral peripheral arterial disease. Circulation 1999; 99: 807-12.
25. Wang H, Hiatt WR, Barstow TJ, Brass EP. Relationships between muscle mitochondrial DNA content, mitochondrial enzyme activity and oxidative capacity in man: alterations with disease. Eur J Appl Physiol 1999; 80: 22-27.
26. Bieber LL, Carnitine. Annu Rev Biochem 1988; 57: 261-83.
27. Brass EP, Hoppel CL. Relationship between acid-soluble carnitine and coenzyme A pools in vivo. Biochem J 1980; 190: 495-504.
28. Hoppel CL. Determination of carnitine. In: Hammes FA (ed). Techniques in diagnostic human biochemical genetics. New York:Wiley-Liss. 1991: 309-26.
29. Hiatt WR, Wolfel EE, Regensteiner JG, Brass EP. Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. J Appl Physiol 1992; 73: 346-53.
30. Sorlie D, Myhre K. Effect of physical training in intermittent claudication. Scand J Clin Lab Invest 1978; 38: 217-22.
31. Brown GC. Control of respiration and ATP synthesis in mammalian mitochondria and cells. Biochem J 1992; 284: 1-13.
32. 31P magnetic resonance spectroscopy of abnormal mitochondrial oxidation during recovery from exercise. NMR Biomed 1993; 6: 302-10.
33. Barstow TJ, Buchthal S, Zanconato S, Cooper DM. Muscle energetics and pulmonary oxygen uptake kinetics during moderate exercise. J Appl Physiol 1994; 77: 1742-49.
34. Bauer TA, Regensteiner JG, Brass EP, Hiatt WR. Oxygen uptake kinetics during exercise are slowed in patients with peripheral arterial disease. J Appl Physiol 1999; 87: 809-16.
35. Karmazyn M. Ischemic and repertusion injury in the heart: cellular mechanisms and pharmacologic interventions. Can J Physiol Pharmacol 1991; 69: 719-30.
36. Turrens JF, Beconi M, Barilla J. Chavez UB, McCord JM. Mitochondrial generation of oxygen radicals during rcoxygcnation of ischemic tissues. Free Radic Res Commun 1991; 12: 681-89.
37. Mehta JL, Nichols WW, Mehta P. Neutrophils as potential participants in acute myocardial ischemia: relevance to reperfusion. J Am Coll Cardiol 1988; 11: 1306-16.
38. Hickman P, Harrison DK, Mill A et al. Exercise in patients with intermittent claudication results in the generation of oxygen derived free radicals and endothelial damage. Adv Exp Med Biol 1994; 361: 565-70.
39. Belch JJF, Mackey IR, Hill A, Jennings P, McCallum P. Oxidative stress is present in atherosclerotic peripheral arterial disease and further increased by diabetes mellitus. Int Angiol 1995; 14: 385-88.
40. Neumann FJ, Waas W, Diehm C et al. Activation and decreased deformability of neutrophils after intermittent claudication. Circulation 1990; 82: 922-29.
41. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993; 90: 7915-22.
42. Davies KJA, Delsingore ME. Protein damage and degradation by oxygen radicals. J Biol Chem 1987; 262: 9908-13.
43. Tritsehler H-J, Meduri R. Mitochondrial DNA alterations as a source of human disorders. Neurology 1993; 43: 280-88.
44. Melov S, Shoffner JM, Kaufman A, Wallace DC. Marked increase in the number and variety of mitochondrial DNA rearrangements in aging skeletal muscle. Nucl Acid Res 1995; 23: 4122-26.
45. Corral-Debrinski M, Shoffner JM, Lott MT, Wallace DC. Association of mitochrondrial DNA damage with aging and coronary atherosclerotic heart disease. Mutation Res 1992; 275: 169-80.
46. Campos Y, Huertas R, Lorenzo G et al. Plasma carnitine insufficiency and effectiveness of L-carniline therapy in patients with mitochondrial myopathy. Muscle Nerve 1993; 16: 150-53.
47. Lopaschuk GD, Wall SR, Olley PM, Davies NJ. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res 1988; 63: 1036-43.
48. McCormack JG, Barr RJ, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in hypoxic, ischemic, and reperfused ischemic rat hearts. Circulation 1996; 93: 135-42.
49. Brass EP. Skeletal muscle metabolism as a target for drug therapy in peripheral arterial disease. Vasc Med 1996; 1: 55-59.
50. Brevetti G, Perna S, Sabba C, Martone VD, Condorelli M. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose-titration, multicenter study. J Am Coll Cardiol 1995; 26: 1411-16.